14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ALAB vs CBRS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Astera Labs, Inc. (ALAB) is the stronger overall head-to-head candidate over Cerebras Systems Inc. (CBRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALAB carries a Unified Composite Score of 57.4/100 (HOLD) at $202.34 (28.3x Forward P/E, 25.5% operating margin), whereas CBRS carries 54.4/100 (HOLD) at $100.99 (N/M Forward P/E, -265.0% operating margin).
Technical & Structure Timing Caution: ALAB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8); meanwhile CBRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Semiconductors & Related Devices value chain with N/A market capitalization and -265.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ALAB vs CBRS Key Questions & Quantitative Answers
As of Nov 16, 2026, Astera Labs, Inc. (ALAB) is the stronger overall head-to-head candidate over Cerebras Systems Inc. (CBRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALAB carries a Unified Composite Score of 57.4/100 (HOLD) at $202.34 (28.3x Forward P/E, 25.5% operating margin), whereas CBRS carries 54.4/100 (HOLD) at $100.99 (N/M Forward P/E, -265.0% operating margin). Technical & Structure Timing Caution: ALAB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8); meanwhile CBRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ALAB leads the Growth & Scale pillar: ALAB posts +153.7% YoY revenue growth and +98.0% YoY earnings growth on $1.56B TTM revenue (73.9% gross margin, 25.5% operating margin), compared with CBRS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, -265.0% operating margin). Across the 7-period historical trajectory (Q1 '25 to Q3 '26), ALAB cumulative revenue shifted +154.3% while CBRS shifted +80.0%. In operating R&D and SG&A reinvestment, ALAB deploys 48.4% of Rev ($753M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CBRS.
ALAB screens cheaper on headline valuation multiples. ALAB trades at 28.3x Forward P/E, 87.7x Trailing P/E, N/M PEG, and 24.9x EV/Revenue (22.1% FCF margin), whereas CBRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALAB (28.2% ROE) versus CBRS (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ALAB carries 141.7% implied volatility (68th %ile, Elevated (60th–80th %ile)), a 1.36x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (4.24β · 124% Vol realized risk). By comparison, CBRS carries 132.3% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 1.39x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.85β · 109% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.